Baraliakos X, et al. Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial. ACR 2018, abstract L13.
Bimekizumab bij axiale spondyloartritis: BE MOBILE 1 en 2
apr 2023 | Spondyloartritis